HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudy.

Abstract
Although measurement of troponin is widely used for diagnosing acute myocardial infarction (AMI), its diagnostic potential may be increased by a more complete characterization of its molecular appearance and degradation in the blood. The aim of this study was to define the time course of cardiac troponin I (cTnI) degradation in patients with acute ST-elevation myocardial infarction (STEMI). In the ASSENT-2 substudy, 26 males hospitalized with STEMI were randomized to 2 different thrombolytic drugs within 6 hours after onset of symptoms. Blood samples were obtained just before initiation of thrombolysis and at 30 minutes intervals (7 samples per patient). Western blot analysis was performed using anti-cTnI antibodies and compared with serum concentrations of cTnI. All patients exceeded the cTnI cutoff for AMI during the sampling period; at initiation of therapy, 23 had elevated cTnI values. All patients demonstrated 2 bands on immunoblot: intact cTnI and a single degradation product as early as 90 minutes after onset of symptoms. On subsequent samples, 15 of 26 patients showed multiple degradation products with up to 7 degradation bands. The appearance of fragments was correlated with higher levels of cTnI (P<0.001) and time to initiation of treatment (P=0.058). This study defines for the first time the initial time course of cTnI degradation in STEMI. Intact cTnI and a single degradation product were detectable on immunoblot as early as 90 minutes after onset of symptoms with further degradation after 165 minutes. Infarct size and time to initiation of treatment was the major determinant for degradation.
AuthorsLene H Madsen, Geir Christensen, Terje Lund, Victor L Serebruany, Chris B Granger, Ingvild Hoen, Zanina Grieg, John H Alexander, Allan S Jaffe, Jennifer E Van Eyk, Dan Atar
JournalCirculation research (Circ Res) Vol. 99 Issue 10 Pg. 1141-7 (Nov 10 2006) ISSN: 1524-4571 [Electronic] United States
PMID17038641 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Epitopes
  • Fibrinolytic Agents
  • Troponin I
  • Tissue Plasminogen Activator
  • Tenecteplase
Topics
  • Adult
  • Aged
  • Antibodies, Monoclonal (chemistry, immunology)
  • Blotting, Western
  • Electrophoresis, Polyacrylamide Gel
  • Epitopes (analysis)
  • Fibrinolytic Agents (therapeutic use)
  • Humans
  • Immunoprecipitation
  • Male
  • Middle Aged
  • Myocardial Infarction (blood, drug therapy)
  • Tenecteplase
  • Tissue Plasminogen Activator (therapeutic use)
  • Troponin I (blood, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: